Medline ® Abstract for Reference 26

of 'Treatment of central diabetes insipidus'

26
TI
Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus.
AU
Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M
SO
Arch Intern Med. 1989;149(5):1123.
 
Nephrogenic diabetes insipidus (NDI) is a frequent complication in patients receiving long-term lithium therapy. Both thiazide diuretics and amiloride may reduce the polyuria, but the use of each is associated with problems. We report the results of a clinical trial using the nonsteroidal anti-inflammatory drug indomethacin to treat a patient with well-documented lithium-induced NDI that persisted following cessation of lithium treatment. The administration of a single dose of indomethacin resulted in a dramatic decrease in urine volume and increase in urine osmolality that persisted for several hours, and was independent of renal hemodynamic changes. Subsequently, the patient experienced a sustained, favorable effect on her polyuria during long-term (3 months) indomethacin therapy without a deleterious effect on her renal function. Indomethacin may be a useful therapeutic tool for the amelioration of lithium-induced NDI.
AD
Department of Medicine, University of Oklahoma School of Medicine, Oklahoma City 73104.
PMID